YKL-40 as marker of severe lung disease in cystic fibrosis patients

详细信息    查看全文

• 作者：Salvatore Leonardi^a ; ^{leonardi@unict.it" class="auth_mail" title="E-mail the corresponding author} ; Giuseppe Fabio Parisi^a ; Antonino Capizzi^a ; Sara Manti^b ; Caterina Cuppari^b ; Maria Grazia Scuderi^c ; Novella Rotolo^a ; Angela Lanzafame^a ; Maria Musumeci^d ; Carmelo Salpietro^b
• 关键词：YKL-40 ; Cystic fibrosis ; Pulmonary pseudomonas infection ; Acute pulmonary exacerbation ; Lung function decline
• 刊名：Journal of Cystic Fibrosis
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：15
• 期：5
• 页码：583-586
• 全文大小：251 K

文摘

YKL-40 is a chitinase-like protein present in serum of healthy subjects and its levels are increased in several human inflammatory diseases. The aim of this study was to evaluate the levels of both serum and sputum YKL-40 in cystic fibrosis (CF) patients.

Methods

Serum and sputum YKL-40 levels were measured in a cohort of twenty-eight patients with a diagnosis of CF and twenty healthy controls.

Results

Serum YKL-40 levels were significantly higher in CF patients (88.8 ± 56.7 vs 18.6 ± 2.9 ng/ml, P < 0.001), as well as sputum YKL-40 levels (138.5 ± 132.7 vs 28.2 ± 24.34, P < 0.001) than in healthy controls. Serum YKL-40 levels were closely related to YKL-40 levels assessed in sputum samples (r = 0.71; P < 0.01).

Conclusions

YKL-40 is elevated in CF patients and is further elevated during severe exacerbations. Longitudinal studies in infant are needed to establish its role in disease pathogenesis.